Based on the aggregated intelligence of 135,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device maker Becton, Dickinson (NYSE:BDX) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Becton Dickinson's business and see what CAPS investors are saying about the stock right now.

Becton Dickinson facts

Headquarters (founded)

Franklin Lakes, N.J. (1897)

Market Cap

$15.75 billion

Industry

Health-care equipment

TTM Revenue

$7.16 billion

Management

CEO Edward Ludwig (since 2000)
CFO David Elkins (since 2008)

Return on Equity (average, last three years)

23%

Dividend Yield

2%

Competitors

Abbott Labs (NYSE:ABT)
Baxter International (NYSE:BAX)

CAPS members bullish on BDX also bullish on

Johnson & Johnson (NYSE:JNJ)
Procter & Gamble (NYSE:PG)

CAPS members bearish on BDX also bearish on

Monsanto (NYSE:MON)
ExxonMobil (NYSE:XOM)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, fully 513 of the 529 members who have rated Becton Dickinson -- some 97% -- believe the stock will outperform the S&P 500 going forward. These bulls include All-Star claygrant1974, who is ranked in the top 15% of our community, and mgiamalis.

In late June, claygrant1974 touched on the company's massive scale in the surgical products space:

They are leaders in a field that is rock solid and will continue to grow, at least for a few years. Recession proof. Diversified products and global operations. Strong balance sheet. What is not to love?

In a pitch from three days ago, mgiamalis talked price:

This is a high growth stock, which is very undervalued. The company has posted consistent revenue and earnings growth, and has a low [PEG] ratio of 1.1. Their P/E is around 13 which is low relative to their competitors, and relative to their average P/E ratio from years past. The company has a 25% ROE and pays a healthy dividend at a higher yield than its competitors, and with a lower payout ratio, a sign of undervaluation.

What do you think about Becton Dickinson, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 135,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson and Procter & Gamble are Motley Fool Income Investor picks. The Fool owns shares of Procter & Gamble. The Fool's disclosure policy always gets a perfect score.